Racial disparity in survival of patients with uterine serous carcinoma: Changes in clinical characteristics, patterns of care and outcomes over time from 1988 to 2011.
暂无分享,去创建一个
Haider Mahdi | F. Abdul-Karim | R. Vargas | H. Mahdi | Fadi Abdul-Karim | Xiaozhen Han | Roberto Vargas | Xiaozhen Han
[1] O. Yap,et al. Racial and ethnic disparities in cancers of the uterine corpus. , 2006, Journal of the National Medical Association.
[2] R. Burger,et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Olson,et al. The influence of comorbid conditions on racial disparities in endometrial cancer survival. , 2014, American journal of obstetrics and gynecology.
[4] R. Burger,et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Waggoner,et al. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. , 2015, Gynecologic oncology.
[6] Deepa Naishadham,et al. Cancer statistics for African Americans, 2013 , 2013, CA: a cancer journal for clinicians.
[7] E. Yordan,et al. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. , 2011, Gynecologic oncology.
[8] T. Herzog,et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. , 2003, Gynecologic oncology.
[9] V. Abeler,et al. Clear-cell and papillary serous cancer: treatment options. , 2001, Best practice & research. Clinical obstetrics & gynaecology.
[10] R. Kempson,et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma , 1982, The American journal of surgical pathology.
[11] M. Maiman,et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. , 1997, Gynecologic oncology.
[12] J. Thigpen,et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Racial Disparities in Treatment of High-Grade Endometrial Cancer in the Medicare Population , 2015, Obstetrics and gynecology.
[14] L. Havrilesky,et al. Platinum/taxane‐based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma , 2009, Cancer.
[15] R. Bentley,et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] K. Armstrong,et al. Differences in treatment and outcome between African-American and white women with endometrial cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Gruber,et al. Endometrial cancer: socioeconomic status and racial/ethnic differences in stage at diagnosis, treatment, and survival. , 2004, American journal of public health.
[18] F. Montz,et al. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. , 2001, Gynecologic oncology.
[19] Alicia Samuels,et al. Cancer Statistics for African Americans , 2002, CA: a cancer journal for clinicians.
[20] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[21] Nobuyuki Susumu,et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.
[22] G. Maxwell,et al. Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. , 2009, Cancer control : journal of the Moffitt Cancer Center.
[23] R. Berkowitz,et al. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. , 2014, Gynecologic oncology.
[24] G. Parham,et al. The National Cancer Data Base report on endometrial carcinoma in African‐American women , 1998, Cancer.
[25] G. Fleming,et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma , 2006, Cancer.
[26] M. Rotman,et al. Poor survival of black patients in carcinoma of the endometrium. , 1993, International journal of radiation oncology, biology, physics.
[27] R. Burger,et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. McAlpine,et al. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. , 2004, Gynecologic oncology.
[29] J. Nicklin,et al. Endometrial papillary serous carcinoma: patterns of spread and treatment. , 1996, Clinical obstetrics and gynecology.